Immix Biopharma, Inc. (IMMX) stock
IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.11−0.09 (-1.25%)
Close on Nov 18, 2026Market cap $508.64MP/E –Yield –
Immix Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Immix Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$41.82M. For fiscal 2025 it was -$29.96M. The highest annual figure on record is -$453.85K in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$29.96M | – |
| FY2024 | Dec 31, 2024 | -$22.67M | – |
| FY2023 | Dec 31, 2023 | -$16.14M | – |
| FY2022 | Dec 31, 2022 | -$8.22M | – |
| FY2021 | Dec 31, 2021 | -$1.35M | – |
| FY2020 | Dec 31, 2020 | -$453.85K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.46M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.80M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.89M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.66M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.68M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.99M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.59M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.52M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.72M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.52M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.53M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.56M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.33M | – |
| Q4 FY2021 | Dec 31, 2021 | -$598.34K | – |
| Q3 FY2021 | Sep 30, 2021 | -$347.99K | – |
| Q2 FY2021 | Jun 30, 2021 | -$243.17K | – |
| Q1 FY2021 | Mar 31, 2021 | -$162.52K | – |
See a number that looks wrong?